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Abstract
 
Maturation of dendritic cells (DCs) is a critical step for the induction of an immune response.
We have examined the role of retinoid nuclear receptor pathways in this process. Retinoids in-
duce DC apoptosis, in the absence of inflammatory signals, through retinoic acid receptor
(RAR)
 
 
 
/retinoic X receptor (RXR) heterodimers. In contrast, via a cross talk with inflamma-
tory cytokines, retinoids increase DNA binding activity of nuclear factor 
 
 
 
B in DCs, trigger
membrane major histocompatibility complex class II and costimulatory molecule expression,
induce the differentiation of immature DCs into mature DCs, and enhance antigen-specific T
cell response. This maturation of DCs is mediated via a RXR-dependent/RAR-independent
pathway and via an RAR
 
 
 
/RXR pathway distinct from the one responsible for apoptosis.
Apoptosis and activation, mediated through distinct nuclear retinoid receptor pathways, can be
dissociated from each other with selective synthetic retinoids. We identify a novel cellular
function for retinoids and suggest that selective retinoids might be of interest for controlling
antigen presentation.
Key words: human • cellular activation • antigen presentation • immunomodulators • nuclear 
receptors
 
Introduction
 
The generation of adaptive immune response against for-
eign antigen requires the participation of both antigen-
specific T cells and antigen-presenting cells. DCs have the
capacity to sample antigen at the boundary with the “exter-
nal milieu” and migrate toward T cell areas of the draining
lymph node. There, they can provide processed antigen
together with the costimulatory signals required for the
proliferation of antigen-specific T cells (1). The maturation
process of DCs is thus believed to be critical for the induc-
tion of an immune response. Retinoids, through their
cognate nuclear retinoid receptors, transactivate numerous
genes and exert potent effects in development and he-
mopoiesis (2). Retinol (Rol; vitamin A) is metabolized
intracellularly via two distinct pathways forming its active
derivatives: (a) retinoic acids (RAs), all-trans RA (tRA) and
9-cis RA (9cRA), whose effects are transduced by nuclear
retinoid receptors (RA receptors [RARs] and retinoic X
receptors [RXRs]; 2), and (b) retro-retinoids, which do
not bind to known receptors (3). Rol was shown to en-
hance T cell–mediated host versus graft response in mice,
augment specific antitumor immunity, and impair acquired
immunological tolerance of foreign cells (4–7). Conversely,
several studies have shown that vitamin A–deficient rodents
fail to elicit full immune response to viral and bacterial
pathogens (8), and field studies have convincingly shown
that Rol supplementation reduces mortality from infectious
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Abbreviations used in this paper:
 
 9cRA, 9-cis retinoic acid; LC, Langerhans
cell; NF, nuclear factor; PI, propidium iodide; RA, retinoic acid; RAR,
RA receptor; Rol, retinol; RXR, retinoic X receptor; tRA, all-trans RA;
TT, tetanus toxoid.T
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diseases among children in areas where vitamin A defi-
ciency is endemic (9–12). The cellular and molecular
mechanisms that underlie the effect of retinoids on the im-
mune system remains elusive. Vitamin A was shown to en-
hance B and T cell survival and proliferation in vitro (3, 13,
14). These effects are triggered by retro-retinoids, and B
and T cells do not synthesize RA in appreciable amounts
(3, 13, 14). 9cRA did not affect thymocyte proliferation,
but was shown to be a potent negative regulator of activa-
tion-induced T cell apoptosis (15), likely through RAR/
RXR heterodimers (16). The effects of retinoids on im-
mune responses might also be mediated by DCs. Mice fed
with a diet containing vitamin A acetate or 13-cis-RA
presented with an increase in the number of accessory cells
in the paracortical region of the lymph nodes and in
splenic marginal zone (17). The antigen-presenting cell
function of these cells was increased as evidenced by both
alloproliferative and allocytotoxic responses in vitro (17).
Activation of Langerhans cells (LCs) after topical adminis-
tration of RA have been reported (18). Opposite effects of
retinoids has also been reported, which include decreased
antigen-presenting cell function in vitro, a toxic effect on
epidermal LCs, and decreased response to vaccinal antigen
in vivo (19–23).
This study aimed to investigate the various potential ef-
fects of retinoids on DCs and dissect the nuclear pathways
that underlie these effects. Here we report that retinoids,
through their cognate nuclear receptors, act in vitro on im-
mature DCs to induce either their activation or their apop-
tosis, in the presence or absence of inflammatory signals,
respectively. Using receptor-selective retinoid ligands (see
Table I), we show that the effects of retinoids on immature
DCs are mediated through distinct retinoid receptor path-
ways that can be dissociated from each other. Our data
identify new pathways and potential tools for the regulation
of antigen presentation by DCs.
 
Materials and Methods
 
Culture of DCs.
 
Immature DCs with the LC phenotype
(CD1a
 
 
 
, E-cadherin
 
 
 
, CLA
 
 
 
, CMHII
 
lo
 
, CD86
 
 
 
, TNFRI
 
lo
 
)
among which 20–40% express Lag and Langerin (see Fig. 4), with
high pinocytic and weak antigen presentation activities, were ob-
tained as previously described (24, 25) from purified blood
CD14
 
  
 
human monocytes cultured for 5–7 d in RPMI 1640 sup-
plemented with 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, 100
 
 
 
g/ml streptomycin, 10% heat-inactivated FCS Myoclone (all
from GIBCO BRL), 100 ng/ml GM-CSF (Sandoz AG), 10 ng/
ml IL-4 and 10 ng /ml TGF
 
  
 
1 (R&D Systems), and referred to
as LC-type DC. These immature DCs mature after CD40L trig-
gering (as a surrogate cognate signal; 25).
 
Retinoids and Cytokines.
 
tRA was from Sigma-Aldrich and
Rol and 9cRA were from Calbiochem. RAR
 
  
 
(BMS614),
RAR
 
  
 
(BMS 641 and BMS453), RAR
 
  
 
(BMS961) agonists,
RAR
 
  
 
(BMS 614) and pan-RAR (BMS493) antagonists, and the
pan-RXR agonist (SR11237) were provided by Bristol-Myers
Squibb (see Table 1; references 26–30). All retinoids were stored
dissolved in ethanol at 10
 
 
 
3 
 
M. Human recombinant TNF
 
  
 
and
IL-1
 
  
 
were from R&D Systems. Human holoRBP, fully satu-
rated by Rol, was purified from plasma as previously described
(31) and stored in Tris-HCl 20 mM buffer, pH 7.4. Murine fi-
broblast cell lines transfected with human CD40L were provided
by F. Brière (Schering-Plough, Dardilly, France).
 
Flow Cytometry Analysis.
 
10
 
5 
 
cells were incubated in 96-well
plates (Becton Dickinson) for 15 min at 4
 
 
 
C in PBS, 2% human
AB serum, and 0.01 M NaN
 
3
 
, with FITC-conjugated anti-DR
(Immunotech) and PE-conjugated CD86 (BD Biosciences) at the
appropriate concentration, or with control isotype-matched irrel-
evant mAbs at the same concentration. After washing, 10
 
4 
 
events
were analyzed with a FACSCalibur™ (Becton Dickinson) using
CELLQuest™ software (Becton Dickinson). For apoptosis stud-
ies, 4 
 
  
 
10
 
5 
 
cells were washed and either nuclei were stained with
propidium iodide (PI; 50 
 
 
 
g/ml in PBS 0.1 NaCi, 0.1% Triton
X-100 for 20 min at 37
 
 
 
C) or, alternatively, cells were incubated
for 15 min at 4
 
 
 
C in PBS, 2% human AB serum, and 0.01 M
NaN
 
3
 
, with annexin V and 2 
 
 
 
g/ml PI. 2 
 
  
 
10
 
4 
 
events were
then analyzed with a FACSCalibur™ (Becton Dickinson) using
CELLQuest™ software (Becton Dickinson).
 
Confocal Microscopy.
 
Cells were washed in Ca
 
2
 
 
 
/Mg
 
  
 
-free
PBS and were allowed to adhere to glass slides coated with 50
 
 
 
g/ml poly-
 
l
 
-lysine (Sigma-Aldrich) for 30 min. Slides were
washed and fixed with PBS 4% paraformaldehyde for 30 min,
incubated with PBS 0.1 M glycine for 10 min, and kept at 4
 
 
 
C
in PBS 0.01 M sodium azide. For staining, slides were incubated
for 30 min at room temperature with mouse anti–human Lan-
gerin (provided by S. Saeland, Schering-Plough Laboratory for
Immunological Research, Dardilly, France; 32, 33) followed by
goat anti–mouse Cy3. Slides were washed and incubated with
10% mouse serum for 20 min and then incubated with FITC-
conjugated mAb to HLA-DR (Immunotech). Slides were
mounted with Fluoprep (Biomerieux SA) and analyzed with a
confocal laser microscope system (LSM510; Carl Zeiss MicroIm-
aging, Inc.) attached to a microscope (Axiovert 200M; Carl Zeiss
MicroImaging, Inc.).
 
Antigen Presentation Assays.
 
DCs were collected, washed three
times, pulsed for 8 h with tetanus toxin or medium alone, then
for 40 h with or without retinoids and 10 ng/ml TNF
 
 
 
. Cells
were washed two times in RPMI with 10% human AB serum,
resuspended in RPMI with 10% human AB serum, and added
in triplicate at various concentrations to 10
 
5 
 
autologous (auto-
logous antigen presentation assay) or allogenous (MLR) T cells/
well in 96-well tissue culture plates (Falcon). T cells were iso-
lated by the standard Ficoll-Paque method followed by mag-
netic depletion of non–T cells (MACS; Miltenyi Biotec).
[
 
3
 
H]thymidine (Amersham Biosciences) incorporation was mea-
sured in newly synthesized DNA over 18 h, using pulses initi-
ated at days 4 or 5 of the culture with 1 mCi/well of [
 
3
 
H]thymi-
dine. Cells were then harvested with a 96-well Harvester
(Amersham Biosciences), collected on glass fiber filter (Amer-
sham Biosciences), and the incorporation of thymidine was mea-
sured with a Beta-plate microscintillation counter (LKB; Amer-
sham Biosciences).
 
Electrophoretic Mobility Shift Assay.
 
4 
 
  
 
10
 
6 
 
cells were washed
once in cold PBS and allowed to swell on ice for 10 min in buffer
A (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5
mM DTT, and 2 mM PMSF) containing the following protease
inhibitors: leupeptin, aprotinin, pepstatin, and antipain, each at a
concentration of 4 
 
 
 
g/ml. Samples were then centrifuged and the
pellet was suspended in 20 
 
 
 
l buffer C (20 mM Hepes, pH 7.8,
420 mM NaCl, 1.5 mM MgCl2, 0.5 mM DTT, and 2 mM
PMSF) containing the protease inhibitors. The mixture was left
for 20 min on ice. Cell debris were removed by centrifugationT
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and the resulting nuclear extracts were stored at 
 
 
 
70
 
 
 
C. Protein
concentration was measured with the Bio-Rad protein assay
(Bio-Rad Laboratories). Nuclear extracts (5–10 
 
 
 
g protein) were
assayed for DNA binding activity in a total volume of 20 
 
 
 
l bind-
ing buffer (20 mM Tris-HCl, pH 8, 60 mM KCl, 2 mM MgCl2,
0.3 mM DTT, 12% glycerol, and 3 
 
 
 
g poly dI-dC). Nuclear ex-
tracts were incubated separately for 15 min at 30
 
 
 
C with the dou-
ble stranded labeled probes for nuclear factor (NF)-
 
 
 
B (5
 
 
 
-
GATCCCAAGAGGGATTTCACCTAAATCC-3
 
 
 
). The sam-
ples were then loaded onto a nondenaturing 5% polyacrylamide
gel and subjected to electrophoresis at 14 V/cm in a low ionic
strength buffer (0.5X TBE). Gels were dried and examined with a
PhosphorImager (Molecular Dynamics).
 
Quantitation of IL-12 Production by ELISA.
 
Supernatants were
stored at 
 
 
 
70
 
 
 
C until cytokine measurements. Production of
bioactive IL-12 p70 were measured in duplicate using ELISA
Quantikine Kits (R&D Systems) according to the manufacturer’s
instructions. Sensitivity of IL-12 detection was 0.5 pg/ml.
 
Statistics.
 
Student’s 
 
t
 
 test was used to interpret the significance
of differences between experimental groups (presented as mean 
 
 
 
SD). P value was two tailed and considered significant when
 
 
 
0.05.
 
Results
 
Apoptosis of Immature DCs Is Mediated through RAR
 
 
 
-
RXR Nuclear RAR Heterodimers.
 
Immature DCs with the
LC (LC-type DCs) phenotype (refer to Materials and
Methods) cultured with retinoids rapidly died. 1 
 
 
 
M Rol
significantly induced the death of immature LC-type DCs
with a 20 and 40% reduction of viable cell numbers after 2
and 3 d, respectively (Fig. 1 a). The active derivatives of
Rol, tRAs and 9cRAs, induced a similar dose- and time-
dependent cell death as determined by the reduction of vi-
able cell number and the percentage of apoptotic nuclei
(Table II and unpublished data). This effect was restricted
to DCs at their immature stage of differentiation because
neither mature DCs (CD40L-treated) nor monocytes (from
days 0 to 4 of culture with cytokines) died after exposure to
retinoids (unpublished data). Dying cells expressed annexin
Figure 1. Retinoids induce dose- and time-dependent apoptosis of
LC-type DCs. (a) Day 6 immature LC-type DCs were cultured in the ab-
sence ( ) or presence of increasing amounts ( , 10 nM;  , 100 nM;  ,
1,000 nM) of Rol and viable cells were counted each day with trypan
blue exclusion. (b) After day 2 of culture in the presence of the indicated
amounts of tRA, cells were washed and incubated with anti–annexin V
antibody and 2  g/ml PI. 104 total events (without gating) were then an-
alyzed with a FACSCalibur™ (Becton Dickinson) using CELLQuest™
software (Becton Dickinson). Data are representative of three experi-
ments on different donors.
 
Table I.
 
Functional Characteristics of Retinoids
 
Retinoid nuclear receptors
Ligands
RAR
 
 
 
AF2
RAR
 
 
 
AF2
RAR
 
 
 
AF2
RXR
AF2
(RXR)2
DR1
RAR
 
 
 
-RXR
DR5 References
Natural ligands
tRA
 
   
 
00
 
 
 
2
9cRA
 
        
 
2
Synthetic ligands
BMS753
 
 
 
00 00
 
 
 
30
BMS614
 
 
 
a
 
00 00
 
 
 
28
BMS641 0
 
 
 
0 0 ND ND 27
BMS453
 
   
 
0N D N D 2 7
BMS961 0 (
 
 
 
)
 
 
 
00 0 3 0
BMS493
 
   
 
0N D N D 2 6
SR11237 0 0 0
 
  
 
0 28–30
BMS749
 
      
 
04 0
Transcriptional activities of retinoids used in this study have been previously determined using reporter cells for the AF2 functions of RARs (
 
 
 
, 
 
 
 
,
or 
 
 
 
), and RXRs, whereas RXR
 
  
 
homodimer [(RXR)2] activity on a DR1-tk-CAT reporter gene and RAR
 
 
 
-RXR
 
  
 
heterodimer activity on a
DR5-tk-CAT reporter gene were determined by transient transfections (references 26-29 and unpublished data). 
 
 , agonist; ( ), weak agonist;  ,
antagonist; 0, absence of agonist and antagonist activities.
aMay in some instances synergize with an RXR agonist (reference 28).T
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V (Fig. 1 b) and death was blocked by the caspase inhibitor
Z-Vad-fmk (Table II), but not by anti-Fas blocking anti-
body ZB4, even though LCs express Fas (unpublished
data), indicating a FasL-independent apoptosis. Moreover a
pan-RAR ( ,   , and  ) antagonist (BMS493; reference
26), inhibited Rol-induced and tRA-induced apoptosis
(Fig. 1 and Table II), demonstrating that apoptosis was me-
diated through RAs and their receptors.
Retinoid nuclear receptor signal transduction is most
frequently transduced by heterodimers composed of RARs
and RXRs (2). RT-PCR analysis revealed that LC-type
cells expressed transcripts for all three RARs ( ,  , and  )
and all three RXRs ( ,  , and  ; unpublished data). A
panel of synthetic retinoid ligands (Table I) was then used
to further investigate which receptors (among RARs and
RXRs) were involved in the effect of retinoids. The results
are summarized in Tables III and IV. Apoptosis of imma-
ture LC-type DCs was induced by a selective RAR  ago-
nist (BMS753; reference 30), but not by RAR  agonists
(BMS 641, BMS453; reference 27), an RAR  BMS961
agonist (30), or a pan-RXR agonist (SR11237; references
28–30; Table III). An RAR -selective antagonist (BMS
614, slt; reference 28) inhibited tRA and BMS753-induced
apoptosis (Table II). These results indicate that the apop-
totic effect of RA is transduced by RAR . The pan-RXR
agonist (SR11237), which had no effects on its own, had a
synergistic effect on LC-type DC apoptosis induced by the
selective RAR  agonist BMS753 (Table IV). The RAR 
agonists BMS641 and BMS453, but not the selective
RAR   agonist (BMS961), also synergize with the pan-
RXR agonist to induce LC-type DC apoptosis (Table IV),
albeit with a lower efficiency. Thus, the retinoid-triggered
LC-type DC apoptosis is transduced by RAR /RXR het-
erodimers in which the transcriptional activity of RXR is
subordinated to ligand binding to its RAR partner (27, 28,
34). Furthermore, RAR -RXR heterodimers can also
transduce the apoptotic effect of retinoids, albeit with a
lower efficiency.
Retinoid-induced Apoptosis Requires Supraphysiological Levels
of Retinoids and Is Inhibited by Inflammatory Cytokines. The
above data may account, at least in part, for the reported
inhibitory effect of retinoids on the in vitro allogenous
Table II. Inhibition of Retinoid-induced Apoptosis by RAR Antagonists, Caspase Inhibitor, TNF , and CD40L
0
Rol
1  M
tRA
1  M
BMS753
1  M BMS753 100 nM   SR11237 100 nM
Medium  5 17   8 38   10 38   8 38   5
BMS614 (1  M)  5— 15   89     57     3
BMS493 (1  M)  5 4   1 10   65     34     2
Z-Vad (50 nM)  5— 9   49     7 11   4
TNF  (10 ng/ml)  5 4.5   18     7 11   1 14   2
CD40La  5—  5  5  5
Day 6 immature LC-type DCs were cultured for 48 h with natural and synthetic retinoids or vehicle (ethanol, EtOH), caspase inhibitor Z-Vad-fmk,
or TNF  as indicated. Mean (  SD) percentage of apoptotic ( 2N) particles of 3–10 experiments on different donors as determined by flow
cytometry of PI-stained nuclei is represented.
aCoculture of LCs with 25% irradiated CD40L transfected L cells.
Bold, P   0.01 to   0.001.
Table III. Rol-induced Apoptosis of LC-type DCs Is Mediated via RAR -RXR Heterodimers
BMS ligandsa
EtOH Rol tRA 9cRA 753 453 641 961 SR11237 614 493
1 nM —  5  5  5  5  5  5  5  5  5—
10 nM —  5  5  5  5  5  5  5  5  5  5
50 nM — — — — 18   3—— — — — —
100 nM —  5 14   68     3 27   9  5  5  5  5  5  5
1  M  5 17   8 36   10 30   9 37   7 10   6  5  5  5  5  5
Mean (  SD) percentage of apoptotic ( 2N) particles after 2 d of culture in the presence of retinoids as determined by flow cytometry of PI-stained 
nuclei. 
aSelective RAR  and RAR  agonists (refer to Table I).T
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MLR (19, 23). However, they cannot account for stimula-
tions of the immune response that have been observed
upon retinoid administration in vivo (4, 5, 17). Major dif-
ferences between in vitro and in vivo conditions might be
the availability of retinoids and the environmental inflam-
matory signals encountered by DCs. Inflammatory cyto-
kines, such as TNF  and IL-1 , are known to enhance mi-
gration of immature LCs from the skin to the lymph nodes
(1, 35) and were shown to contribute to immature DC ac-
tivation (1, 36). Therefore, we investigated the effect of reti-
noids on immature LC-type DCs in the presence of such
cytokines. We found that TNF  inhibited in a dose-depen-
dent manner ( 50% inhibition at 1 ng/ml TNF ) the
proapoptotic effects of Rol and tRA, as well as of 9cRA
and of the RAR  selective agonist BMS753 (Fig. 2, a and
b, and Table II). Other stimuli known to contribute to LC
activation such as IL-1  (1–10 ng/ml; not depicted) and
the cognate signal CD40L also inhibited the apoptotic ef-
fect of retinoids (Table II). Therefore, inflammatory or
cognate signals antagonize the effects of retinoids on imma-
ture LC survival. We also investigated whether concentra-
tions of Rol required to induce apoptosis are present in
physiological conditions. Rol is distributed to peripheral
tissues in vivo as a complex with the Rol binding protein
(holoRBP). To approximate the availability of retinoids in
vivo, we thus investigated the effects of purified holoRBP
in this model. We did not observe apoptosis of immature
LC-like cells at concentrations of holoRBP similar to those
observed in steady-state serum in normal individuals (1–2
 M). Therefore, the concentration required to induce
apoptosis might be above physiological levels (Fig. 3).
Synergistic Activation of Immature DCs by Retinoids and In-
flammatory Cytokines. Next, we investigated the effects
of retinoids on immature LC activation. On its own,
TNF , as well as LPS and IL-1 , is not sufficient to in-
duce significant activation (class II and costimulatory
molecule expression and enhancement of antigen presen-
tation) of immature LC-type DCs in vitro (Fig. 2, a–c;
reference 25) because TGF 1 inhibits the activation of
these cells in response to inflammatory stimuli (25, 37,
38). In the absence or at a low concentration of TNF 
( 1 ng/ml), Rol and tRA (Fig. 2, a and b), as well as
9cRA, RAR, and RXR agonists (Fig. 4 a), did not sig-
nificantly induce class II or CD86 up-regulation on im-
mature LC-type DCs.
Strikingly, Rol and tRA, in the presence of TNF  ( 1
ng/ml), induced a dose-dependent increase in the mem-
brane expression of class II and CD86 by LC-type DCs,
which paralleled inhibition of apoptosis (Fig. 2, a and b),
suggesting immunological maturation of LCs. Confocal
microscopy examination (Fig. 2 c) confirmed that exposure
to tRA and TNF  induced class II antigen translocation
from cytoplasmic compartments to the cell surface, and
showed that this was accompanied by other typical changes
observed in maturing DCs such as an increase in cell size
and the formation of numerous thin dendrites (1). These
effects are similar to what is observed after DC maturation
in response to CD40L (Fig. 2 c). 9cRA and the selective
RAR  agonist BMS753 had similar effects as Rol and tRA
on immature LC activation in the presence of TNF  (Fig.
4, a and b). The activation induced by Rol, RAs, and
BMS753 was inhibited by the pan-RAR antagonist
BMS493 (Figs. 2 a and 4 c). Together, the fact that these
chemically distinct compounds exert the same effects and
that this effect is inhibited by the same pan-RAR antago-
nist (BMS493) demonstrates that this effect was mediated
through RAs and their nuclear receptors.
To investigate whether these effects of retinoids on DC
activation might be of physiological relevance we then in-
vestigated the effects of purified holoRBP in this model.
Interestingly, the addition of holoRBP (at a concentration
corresponding to its steady-state serum level in normal in-
dividuals) in the presence of TNF  also induced a dose-
dependent activation of immature DCs (Fig. 3). The acti-
vation induced by holoRBP as well as by free Rol was
inhibited by the pan-RAR antagonist BMS493, demon-
strating that their effect was mediated through RAs and
their receptors (Fig. 3).
Interestingly, the selective RXR agonist SR11237 also
induced LC-type DC activation in the presence of TNF 
(at 1–10 ng/ml; Fig. 4, a and b). In contrast to what is ob-
served with RAR agonists, the effect of SR11237 was not
inhibited by the pan-RAR antagonist BMS493 or by the
RAR  antagonist BMS614. Rather, BMS614 appeared to
synergize with SR11237 to activate LCs (Fig. 4, c–e),
whereas BMS614 had no effect on its own (Fig. 4 a).
We have previously shown that TNF  receptor I (p55,
CD120a) expression on LC-type DCs was very low, due
to the effects of TGF 1 (25) exposure to retinoids thus
might have accounted for the increased response to
TNF  by increasing TNF  receptor expression. How-
ever, flow cytometry analysis did not reveal any change in
CD120a and CD120b expression after exposure to reti-
noids (unpublished data).
Retinoids Increase DNA Binding Activity of NF- B Com-
plexes in Response to TNF . As nuclear translocation and
binding of NF- B complexes to their DNA response ele-
Table IV. Rol-induced Apoptosis of LC-type DCs: Synergistic 
Effect between a pan-RXR Agonist (SR11237) and Selective RAR  
and RAR  Agonists
SR11237 100 nM   BMS ligandsa
753 453 641 614 493 961
1 nM 6   3  5  5  5  5  5
10 nM 25   10 5  5  5  5  5
100 nM 32   7 20   6 16   3  5  5  5
1  M 47   10 19   7 30   2  5  5  5
Mean (  SD) percentage of apoptotic ( 2N) particles after 2 d of
culture in the presence of retinoids as determined by flow cytometry of
PI-stained nuclei.
aSelective RAR  and RAR  agonists (refer to Table I).T
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ment was shown to be involved in DC activation (1, 39),
the effect of retinoids might be to increase the DNA bind-
ing capacity of NF- B. Interestingly, the addition of
TNF  after a short (6-h) exposure to tRA, BMS753 or
SR11237 induced a strong increase in the binding of nu-
clear NF- B complexes to a cognate DNA probe when
compared with nuclear extracts from retinoid-untreated
cells, or from cells treated with the RAR   antagonist
BMS614 (Fig. 5). Retinoids on their own had no detect-
able effect on NF- B complex binding activity. The addi-
tion of 10 nM N-tosyl-L-phenylalanine chloromethyl ke-
tone, which has been reported to inhibit translocation of
NF- B and activation of DCs (39), inhibited by 50% the
increase of class II and CD86 on LC-type DCs treated
with tRA and TNF  without any evidence of toxicity
(unpublished data).
Retinoids Enhance Antigen Presentation to T Cells in the
Presence of TNF . LC-type DCs treated with retinoids
and TNF  significantly increased allogeneic T lympho-
cyte proliferation (MLR; Fig. 6, a and b). To investigate
Figure 2. Rol and tRA cooperate with
TNF  to induce a dose-dependent increase
in the percentage of DRhi-CD86hi LC-type
DCs, which parallels inhibition of apoptosis.
Cells were cultured in the presence of 1  M
Rol (a) or tRA (b) and increasing concen-
tration of TNF . Expression of HLA-DR,
CD86 (see Fig. 1), and apoptosis (percent
 2 N particle; see Table II) were deter-
mined at the same time point on separate
aliquots of the same culture. Data from a
representative experiment out of three on
different donors. (c) Day 6 immature LC-
type DCs were cultured for 40 h with
TNF  and/or tRA, or CD40L transfected
fibroblasts. Cells were then analyzed by
confocal microscopy for MHC class II
(green) and Langerin (red) expression. Al-
though tRA or TNF  on their own do not
induce significant morphological changes,
the combination of them strikingly induces
the formation of many thin dendrites,
MHC class II , at the cell surface. These
morphological changes resemble those that
accompany the maturation induced after
exposure to CD40L. Note the membrane
staining for Langerin on immature cells.T
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the effect of retinoids on an antigen-specific immune re-
sponse, we studied the presentation of tetanus toxoid (TT)
by LC-type DCs to fresh autologous lymphocytes of im-
mune individuals. TT-pulsed LC-type DCs exposed to
TNF  and tRA, or TNF  and SR11237 (Fig. 6 c), in-
duced an increase in the proliferative response of autolo-
gous T lymphocytes as compared with pulsed untreated
LC-type DCs or LC-type DCs incubated with either
TNF  alone or retinoids alone. Note that even though
LC-type DCs were washed several times before coculture,
a direct effect of retinoids on T cells cannot be easily ruled
out because retinoids are highly lipophilic. However, such
an effect appears unlikely, as retinoids and/or TNF -
treated LC-type DCs did not stimulate autologous T lym-
phocytes in the absence of antigen (Fig. 6 c). Furthermore,
T cells do not synthesize RAs in appreciable amounts (14).
Therefore, we conclude from the above results that ret-
inoids cooperate with inflammatory signals to induce activa-
tion of immature LC-type DCs and enhance their ability
for antigen presentation.
IL-12 Production by LC-type DCs Is Not Influenced by Ex-
posure to Retinoids. DCs activate helper T cells through
antigen-restricted class II/TCR and costimulatory mole-
cule interaction (1). It has been proposed that activated
helper T cells then in turn activate DCs/LCs through
CD40L–CD40 interaction (40), resulting in the production
of IL-12 by DCs/LCs (1, 40). We investigated whether
retinoids may directly influence IL-12 production by LC
type-DCs in the absence of T cells. Neither TNF  or ret-
inoids alone, nor the combination of the two, at doses that
induced apoptosis or activation, resulted in a significant
production of IL-12 in culture supernatants in the absence
of CD40 triggering (Fig. 6 d). Conversely, CD40 trigger-
ing increased the production of IL-12 by LC-type DCs,
but this increase was not modified by the addition of ret-
inoids and/or TNF  (Fig. 6 d and unpublished data). Thus
retinoids, which enhance the early phase of LC–T cell anti-
gen-restricted interaction mediated through class II/TCR
and costimulatory molecules, may not replace, nor influ-
ence directly, the outcome of the LC–T cell interaction
mediated through CD40L–CD40 interaction.
Retinoid Receptor Pathways That Can Be Dissociated from
the Apoptotic One Mediate the Effects of Retinoids on DC Acti-
vation. The pan-RXR agonist (SR11237) cooperated
with TNF  to induce expression of CD86 and class II Ag
(Fig. 3, a and b), increase DNA binding activity of NF- B
complexes (Fig. 5), and enhance presentation to anti-
gen-specific T cells (Fig. 6, b and c). The pan-RAR an-
tagonist BMS493 had only a weak effect on this TNF -
SR11237 synergism for LC-type DC activation (Fig. 4,
c–e). In contrast, BMS493 strongly inhibited tRA- and
BMS753-induced apoptosis (Table II), as well as RAR-
dependent activation of LC-type DCs (see below). More-
over, another synthetic retinoid (BMS749), which acts as
both a pan-RXR agonist and a pan-RAR antagonist
(41), also cooperated with TNF   to activate LC-type
DCs (unpublished data). Note that neither SR11237 (Ta-
ble II) nor BMS749 (not depicted) exhibited an apoptotic
effect on their own. Thus, activation of immature LC-
type DCs in synergy with TNF  can be achieved via an
RXR pathway that is RAR independent and not in-
volved in apoptosis.
On the other hand, the synergistic effects between either
Rol, tRA, or the RAR  agonist BMS753 and TNF  on
LC-type DC activation, were inhibited by the pan-RAR
antagonist BMS493 (Fig. 3 and unpublished data), demon-
strating that an RAR -dependent pathway could also
induce activation. Interestingly, the RAR   antagonist
BMS614 synergized with the RXR agonist SR11237 for
TNF -induced LC-type DC activation (Fig. 4, c–e) and
antigen presentation (Fig. 6, b and c). This synergistic effect
was inhibited by BMS493 (Fig. 4 d), therefore indicating
the involvement of RXR/RAR  heterodimers. Note that
BMS614 did not induce, but inhibited retinoid-induced
apoptosis (Table II). Natural retinoids and selective ligands
are chemically distinct compounds (2). The fact that they
exert the same effects on cell activation in the presence of
TNF  and that these effects inhibited the pan-RAR antag-
Figure 3. HoloRBP cooperates with TNF  to up-regulate MHC class
II and CD86 on immature LCs. Day 6 immature LCs were cultured in
the presence of 2  M holoRBP purified from human plasma (a) or 1  M
Rol, 1  M holoRBP, or 2  M holoRBP (b) in the presence of 10 ng/ml
TNF  without ( ) or with ( ) 1  M BMS493, and analyzed as indi-
cated in a. Data from one representative experiment is shown. (b) Value
are mean and SD of two separate experiments on different donors. (c)
Day 6 immature LC-type DCs were cultured for 2 d with the indicated
retinoids and then washed and incubated with anti–annexin V antibody
and 2  g/ml PI. 104 total events (without gating) were then analyzed
with a FACSCalibur™ (Becton Dickinson) using CELLQuest™ software
(Becton Dickinson) as described in Fig. 1.T
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onist (BMS493) is strong evidence that the target of reti-
noids are nuclear retinoid receptors.
Together these results demonstrate that the effects of ret-
inoids on LC-type DC activation are efficiently transduced
through both (a) an RXR pathway that is RAR indepen-
dent and (b) an RAR /RXR heterodimer-dependent
pathway, the latter responding to bona fide RAR  agonists
(tRA and BMS753) as well as to the RAR  antago-
nist BMS614 in the presence of the pan-RXR agonist
SR11237.
The RAR   agonists (BMS641 and BMS453) had a
weak effect on the activation of immature LC-type DCs
(Fig. 4 a and unpublished data) and the selective RAR  ag-
onist (BMS961) had no effect whatsoever (unpublished
data). Interestingly, the pan-RAR antagonist BMS493 only
partially blocked 9cRA-induced activation (Fig. 4 c) to a
level similar to that obtained with the RXR agonist
SR11237. This, considered together with the fact that
9cRA binds to both RAR and RXR, suggests that 9cRA
is able to trigger both the RAR-dependent and the RAR-
independent pathways of LC activation.
Discussion
Our present data demonstrate that retinoids act on im-
mature LC-type DCs generated in vitro to regulate either
apoptosis or antigen presentation in the absence or pres-
ence of inflammatory cytokines, respectively. These effects
Figure 4. Retinoid receptor pathways transduce LC-
type DC activation in a cross talk with TNF . (a) Retinoids
cooperate with TNF   to up-regulate MHC class II and
CD86 on immature LC-type DCs. Day 6 immature LC-
type DCs were cultured for 40 h with TNF  and/or reti-
noids or vehicle as indicated. Cells were washed and stained
with HLA-DR-FITC and CD86-PE or isotype controls for
15 min at 4 C. 104 events were then analyzed with a FACS-
Calibur™ (Becton Dickinson) using CELLQuest™ software
(Becton Dickinson). Percents are given for DRhi/CD86hi
cells gated as indicated. Data are representative of 10 experi-
ments on different donors. (b) Synergy between retinoids
and TNF  is dose dependent. In the presence of TNF ,
Rol ( ) tRA ( ), 9cRA ( ), the RAR  agonist BMS753
( ), the RAR  agonist BMS641 ( ), and the RXR agonist
SR11237 ( ) up-regulate MHC class II and costimulatory
CD86 molecules on immature LC-type DCs. The percent-
ages of DRhi/CD86hi cells were plotted against increasing
concentrations (nM) of each retinoid. Results correspond to
one representative experiment. (c–e) Two distinct retinoid
receptor pathways transduce LC-type DC activation in syn-
ergy with TNF . Cells were cultured for 40 h in the pres-
ence of 10 ng/ml TNF  with 100 nM tRA, BMS753, or
9cRA, or with 1,000 nM SR11237, with or without 1,000
nM of the pan-RAR antagonist BMS493 or 1,000 nM of
the RAR  ligand BMS614. (c and d) Percentages of DRhi/
CD86hi cells are represented and results are expressed as the
mean   SD of at least three experiments on different donors.
(e) Cells were cultured in the presence of 10 ng/ml TNF 
with 1,000 nM SR11237 and increasing doses (nM) of
BMS614 ( ) or BMS 493 ( ), or, as controls, with 100 nM
BMS753 and increasing doses (nM) of BMS493 ( ), or with
vehicle (ethanol) and increasing doses (nM) of BMS614 ( ).
The percentages of DRhi/CD86hi cells are presented. Results
are from one representative experiment.
Figure 5. tRA, the RAR   agonist BMS753, the RXR agonist
SR11237, but not vehicle (EtOH) or the RAR  antagonist BMS614,
synergize with TNF  to induce nuclear translocation of NF- B. Day 6
immature LC-type DCs were washed and incubated for 6 h in fresh com-
plete medium alone or with vehicle (ethanol) or retinoids at a 1- M con-
centration. Cells were washed, incubated for 30 min with 50 ng/ml
TNF   or medium alone as control, and then processed for electro-
phoretic mobility shift assay as described in Materials and Methods.T
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are mediated by the active derivatives of vitamin A and
their cognate nuclear receptors. This identifies immature
DCs, such as LCs, as a key cellular target of retinoids and
possibly of vitamin A in the immune system.
DCs are essential antigen-presenting cells that initiate
immune responses. Immature LCs internalize antigens and,
after being activated by inflammatory stimuli and other in-
dicators of cell damage, migrate to T cell areas of secondary
lymphoid organs where they can initiate the immune re-
sponse (1). Epithelial cells produce active TGF   (42),
which is required for the differentiation of malpighian epi-
thelium–associated immature LCs (43), but TGF 1 inhibits
the inflammatory stimuli–mediated activation of immature
LCs (25, 37, 38). Our results suggest a potential role for
retinoids in the activation of immature DCs, such as LCs,
in malpighian epithelia (where most pathogens are encoun-
tered), as upon the addition of retinoids immature LC-type
DCs are synergistically activated in the presence of a mod-
erate amount of inflammatory mediators (1–10 ng/ml
TNF  or IL-1 ), likely to be produced at the site of local
inflammation. Upon the addition of Rol as a complex with
its carrier protein RBP at a concentration close to that ob-
served in the serum of normal individuals (2  M), a pro-
portion of immature LCs are also synergistically activated in
the presence of inflammatory mediators. The mechanism
we describe here may therefore be of physiological rele-
vance and may allow cell damage to be taken into account
at the earliest phase of the cognate immune response by ef-
ficiently triggering an antigen-specific T lymphocyte–
mediated immune response.
In contrast, in the absence of inflammatory stimuli, ret-
inoids on their own do not activate immature LC-type
DCs, rather, increasing concentration to nonphysiological
levels leads to apoptosis in a dose-dependent manner. We
have obtained similar effects of retinoids (apoptosis in the
absence of inflammatory stimuli and enhancement of
TNF -induced activation; unpublished data) in another
model of DCs obtained from human monocytes treated
by GM-CSF and IL-4 (36, 44). Therefore, the opposite
effects of retinoids on the immune response that have
been described, both in vitro and in vivo (4–12, 19–23),
could be related both to the presence and absence of in-
Figure 6. TNF  cooperates with retinoids to increase
antigen presentation by DCs. (a) Rol- and TNF -
treated LC-type DCs increase alloreactive proliferative
response. Immature LC-type DCs were cultured with
TNF   and/or Rol or vehicle for 40 h. Cells were
washed four times in RPMI with 10% human AB serum
and added in triplicate at stimulator/effector ratio of 1
and 4% to 105 purified T cells/well from the same donor
or from a second donor, in 96-well tissue culture plates.
SD are indicated. *, P   0.05. (b) TNF  cooperate with
tRA and RXR agonist to increase alloreactive prolifera-
tive response. Day 6 immature LC-type DCs were cul-
tured with TNF  and/or retinoids or vehicle (ethanol)
for 40 h. Cells were then washed four times in medium
containing 10% human AB serum and added in triplicate
at stimulator/effector ratio of 1 and 4% to 105 purified T
cells/well from the same donor or from a second donor,
in 96-well tissue culture plates. Background thymidine
incorporation was always  10% of alloreactive response.
SD were  15%. *, P   0.01. Results are from one rep-
resentative experiment out of nine on different donors.
(c) TNF  cooperates with retinoids to increase antigen
presentation by immature LC-type DCs. Day 6 imma-
ture LC-type DCs were pulsed for 8 h with TT or me-
dium alone, and then cultured with TNF  and/or ret-
inoids for 40 h. Cells were then washed four times in
medium containing10% human AB serum and added at
stimulator/effector ratio of 4 and 16% to 105 purified T
cells/well from the same donor, in triplicate in 96-well
tissue culture plates. T cell proliferation was measured as
indicated in Materials and Methods. Background thymi-
dine incorporation, in the absence of pulse with TT, is
indicated (no TT) and was always  10% of the antigen-
specific response. SD were  15%. *, P   0.01. Results
are from one representative experiment out of three. (d)
Production of IL-12 upon CD40 triggering. Day 6 im-
mature DCs were incubated for 40 h with 100 nM tRA,
1,000 nM of the RXR agonist SR11237, and/or 10 ng/
ml TNF  and either CD40 liter-transfected fibroblasts
or CD32-transfected fibroblasts as control. Supernatants
were then collected and analyzed for bioactive p70
IL-12 production using ELISA. Results are mean and
SD of five experiments on different donors.T
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flammatory signals and to the doses of retinoids. The dis-
tinct effects of retinoids on immature DCs might have
been related to a signaling imbalance, such as the deliver-
ing of an activation signal by retinoids in the absence of an
appropriate antiapoptotic stimuli. However, the results of
this study do not support this hypothesis because the nu-
clear retinoid receptor pathways that transduce these ef-
fects are distinct.
We demonstrate that the retinoid signal triggering cas-
pase-dependent immature LC-type DC apoptosis in the
absence of inflammatory signals is transduced by RAR /
RXR heterodimers, in which the transcriptional activity of
RXR upon binding of an agonistic ligand is subordinated
(27, 28, 34) to the binding of an agonist ligand to its
RAR  partner (Table II and Fig. 7). As expected, apopto-
sis mediated through RAR /RXR heterodimers is inhib-
ited by RAR antagonists BMS493 and BMS614, and an
RXR agonist (SR11237) does not induce apoptosis on its
own. On the other hand, the retinoid signals that cooperate
with TNF   to induce LC-type DC activation (as evi-
denced by increased DNA binding activity of NF- B com-
plexes, an increase of cell surface expression of class II and
costimulatory molecules, and enhancement of antigen pre-
sentation) are mediated by two distinct pathways that can
be dissociated from the apoptotic one by using synthetic
ligands (Fig. 7). A first pathway is RXR dependent and
RAR independent, as it is induced by RXR-selective ago-
nists (SR11237 and BMS749) and not inhibited by RAR
antagonists (BMS493 and BMS614). The retinoid signal
may be transduced by RXR homodimers acting on DR1
response elements, and/or possibly through heterodimers
between RXR and other nuclear receptors, such as PPARs
or several orphan receptors (2, 41, 45, 46). Note that on its
own, RXR agonist does not induce apoptosis. A second
pathway involves RAR /RXR heterodimers as evidenced
by the induction of LC-type DC activation by the RAR 
selective agonist BMS753, and the synergistic effect of the
RAR -selective ligand BMS614 and the RXR-selective
agonist SR11237 (Fig. 4).
This RAR /RXR pathway is, however, different from
the RAR /RXR pathway responsible for apoptosis of im-
mature LC-type DCs because apoptosis is induced by
RAR  agonists through RAR-RXR heterodimer and is
inhibited by BMS614, whereas in a sharp contrast activa-
tion is synergistically triggered by BMS614 in combination
with an RXR agonist (SR11237).
In this respect, note that BMS614, which inhibits trans-
activation by RAR   from DR5 response elements in
transfection experiments, was already shown in another
instance (28) to synergize with the RXR agonist SR11237
via RAR /RXR heterodimers to induce the differentia-
tion of myeloid cells. Thus, the ligand binding require-
ments of RAR /RXR heterodimers to induce apoptosis
and activation of immature LC-type DCs are different
(Fig. 6), indicating that the responsive genes and/or coac-
tivators proteins involved in these two processes are most
probably different.
Activation of immature DCs in the present model results
from the cooperation of signals transduced by retinoid re-
ceptors and by cytokine receptors. The molecular basis of
this effect is not known. Of note, the present results show
that retinoids and TNF   synergistically induce NF- B
binding to its DNA response element, which has been
shown to be linked to DC activation (39). Future studies
will be needed to explore the mechanisms of this synergis-
tic effect. One possible mechanism would have been the
up-regulation of TNF  receptor p55 by retinoids, however
neither p55 nor p75 receptor expression at the cell mem-
brane as measured by flow cytometry were influenced by
retinoid treatment (unpublished data).
The availability of selective retinoid nuclear receptor
ligands, which dissociate apoptosis and activation of imma-
ture LC-type DCs, may open new avenues for the thera-
peutic control of immune response, e.g., to improve
efficiency of vaccination against certain pathogens or
tumor antigen. For example, an RXR-selective agonist
(SR11237) has no effect on its own on LC-type DC apop-
tosis, whereas it can induce LC-type DC activation, and
the RAR   ligand BMS614 in combination with the
RXR agonist SR11237 stimulates antigen presentation in
the presence of inflammatory cytokines (Fig. 5 c), whereas
it inhibits the RAR /RXR-mediated apoptotic effects of
natural and synthetic retinoids (Table II). The physiologi-
cal role of vitamin A and retinoids on DCs remains un-
known. However, it is of note that Vitamin A deficiency
impairs resistance to infection and increases the risk of
death, particularly to pathogens encountered at epithelial
barriers, and induces an immune defect in response to in-
fection, involving T, B, and NK cells (8–12). Thus, future
studies should explore whether a retinoid-related defect in
immature DC activation might contribute to the immune
defect and the increased mortality due to infection in vita-
min A deficiency.
Figure 7. Effect of retinoids on immature DC survival and activation.
Schematic representation of retinoid receptor pathways that transduce
apoptosis or activation of immature DCs (LC).T
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